Skip to main content

Novel Rx

      RT @uptoTate: Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ trea
      3 years 1 month ago

      Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ treated patients. Interesting concept that needs to be replicated in larger trials. Abs 0193 #ACR21 #RheumNow @RheumNow https://t.co/awqOpwg3gH https://t.co/lGzYglnkyM

      RT @DrPetryna: Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm.
      3 years 1 month ago
      Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2
      RT @drdavidliew: How much ritux for AAV maintenance?

      Ever since we started using it, no-one's been sure.
      If absolute B
      3 years 1 month ago
      How much ritux for AAV maintenance? Ever since we started using it, no-one's been sure. If absolute B cell depletion is your goal, @VUMCRheum data suggest >3.3mg/d is safest for that 500mg q6m = 2.7 mg/d 500mg q4m = 4.1 mg/d 1000mg q6m = 5.5mg/d #ACR21 ABST0416 @RheumNow https://t.co/mYAgKhHT7j
      RT @RichardPAConway: Dr Springer on pharmacological response of RTX in ANCA-vasculitis. Suggest that 500mg every 6 month
      3 years 1 month ago
      Dr Springer on pharmacological response of RTX in ANCA-vasculitis. Suggest that 500mg every 6 months may not achieve sufficient B cell depletion in all. What are the clinical implications? Is anyone dosing 500mg as standard? Abstr#0416 #ACR21 @RheumNow https://t.co/w36hSYbW1B
      RT @drdavidliew: Despite >20y of bDMARDs, our patients still have a 50% greater risk of cardiovascular issues
      (simila
      3 years 1 month ago
      Despite >20y of bDMARDs, our patients still have a 50% greater risk of cardiovascular issues (similar to family history or abdominal obesity) Cardiovascular disease in RA is not historic, it's today's reality we too often ignore. 2020 data @VUamsterdam #ACR21 ABST0286 @RheumNow https://t.co/Az4wHNUOGe
      RT @drdavidliew: PsA bDMARD use in Australia🇦🇺
      (where once you qualify for a bDMARD in general, it's the physician
      3 years 1 month ago
      PsA bDMARD use in Australia🇦🇺 (where once you qualify for a bDMARD in general, it's the physician's free choice) 1. cool Sankey diagram showing switches 2. given the chance, people switch in all directions & switch hard (registry linked with insurance) #ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
      RT @MeralElRamahiMD: Abst#0268
      ➡️Do lipids change w/ some bDMARDs in RA? YES!
      ⭐︎ TCZ: ↑ TC, LDL, TG & ↓
      Abst#0268 ➡️Do lipids change w/ some bDMARDs in RA? YES! ⭐︎ TCZ: ↑ TC, LDL, TG & ↓ in hsCRP relative to initiating TNFi. ➡️Does this lipid ↑ confer risk for CVD? Not necessarily as it may not be atherogenic per Reynolds Risk Score! #ACR21 @Rheumnow https://t.co/Gy62mg6GhZ https://t.co/5uC8Zy0Lbr
      Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe…
      ×